Other analysts also recently issued research reports about the company. Roth Capital raised their price objective on Kalvista Pharmaceuticals from $25.00 to $30.00 and gave the stock a buy rating in a research note on Wednesday, May 15th. Needham & Company LLC initiated coverage on Kalvista Pharmaceuticals in a research note on Wednesday, March 20th. They set a buy rating and a $35.00 price objective on the stock. Finally, Zacks Investment Research downgraded Kalvista Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Thursday, February 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $30.60.
Shares of Kalvista Pharmaceuticals stock opened at $19.15 on Monday. The firm has a market cap of $344.48 million, a P/E ratio of -12.52 and a beta of 2.22. Kalvista Pharmaceuticals has a 12 month low of $7.73 and a 12 month high of $34.92.
Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.22. The business had revenue of $3.89 million for the quarter, compared to the consensus estimate of $3.97 million. Kalvista Pharmaceuticals had a negative return on equity of 19.12% and a negative net margin of 70.08%. Analysts expect that Kalvista Pharmaceuticals will post -1.43 earnings per share for the current fiscal year.
In other Kalvista Pharmaceuticals news, insider Andreas Maetzel sold 5,000 shares of Kalvista Pharmaceuticals stock in a transaction dated Friday, April 5th. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the sale, the insider now owns 5,000 shares of the company’s stock, valued at approximately $150,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Venrock Healthcare Capital Par sold 500,000 shares of Kalvista Pharmaceuticals stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $28.75, for a total value of $14,375,000.00. The disclosure for this sale can be found here. Insiders sold a total of 855,143 shares of company stock worth $24,513,298 in the last three months. Company insiders own 38.40% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Flinton Capital Management LLC acquired a new stake in shares of Kalvista Pharmaceuticals in the 4th quarter valued at about $26,000. Barclays PLC raised its stake in shares of Kalvista Pharmaceuticals by 88,319.7% in the 4th quarter. Barclays PLC now owns 62,778 shares of the specialty pharmaceutical company’s stock valued at $1,240,000 after purchasing an additional 62,707 shares during the period. Polar Capital LLP bought a new position in shares of Kalvista Pharmaceuticals in the 4th quarter valued at about $1,558,000. Vanguard Group Inc. grew its holdings in shares of Kalvista Pharmaceuticals by 152.4% in the 3rd quarter. Vanguard Group Inc. now owns 296,581 shares of the specialty pharmaceutical company’s stock valued at $6,558,000 after acquiring an additional 179,092 shares in the last quarter. Finally, Vanguard Group Inc grew its holdings in shares of Kalvista Pharmaceuticals by 152.4% in the 3rd quarter. Vanguard Group Inc now owns 296,581 shares of the specialty pharmaceutical company’s stock valued at $6,558,000 after acquiring an additional 179,092 shares in the last quarter. 80.64% of the stock is currently owned by hedge funds and other institutional investors.
About Kalvista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Featured Story: How a Back-End Load Mutual Fund Works
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.